BNP Paribas Financial Markets Lowers Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

BNP Paribas Financial Markets cut its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 99.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,833 shares of the specialty pharmaceutical company's stock after selling 6,164,185 shares during the period. BNP Paribas Financial Markets' holdings in Jazz Pharmaceuticals were worth $1,875,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Itau Unibanco Holding S.A. purchased a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter worth about $29,000. EverSource Wealth Advisors LLC boosted its stake in Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock worth $30,000 after acquiring an additional 97 shares in the last quarter. GAMMA Investing LLC grew its holdings in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock worth $31,000 after purchasing an additional 116 shares during the period. Gladius Capital Management LP bought a new position in shares of Jazz Pharmaceuticals during the second quarter valued at approximately $33,000. Finally, Venturi Wealth Management LLC lifted its holdings in shares of Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company's stock valued at $92,000 after purchasing an additional 704 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of several recent research reports. JPMorgan Chase & Co. upped their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an "overweight" rating in a research note on Monday, August 19th. HC Wainwright reissued a "buy" rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Piper Sandler reaffirmed an "overweight" rating and issued a $163.00 price target (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, November 21st. Needham & Company LLC reissued a "buy" rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, November 21st. Finally, Royal Bank of Canada raised their price objective on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an "outperform" rating in a research note on Wednesday, October 23rd. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $175.33.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded down $0.55 during midday trading on Friday, hitting $122.59. 271,650 shares of the stock traded hands, compared to its average volume of 683,863. The firm has a market capitalization of $7.41 billion, a P/E ratio of 17.27, a PEG ratio of 1.04 and a beta of 0.57. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a 50-day moving average of $116.18 and a two-hundred day moving average of $111.59.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 2,000 shares of the firm's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total value of $242,340.00. Following the transaction, the chief executive officer now directly owns 427,025 shares of the company's stock, valued at approximately $51,742,619.25. This trade represents a 0.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Neena M. Patil sold 3,700 shares of the business's stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company's stock, valued at $4,078,453.68. This represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,753 shares of company stock valued at $816,289. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.